ANOVIA, LLC

Biotech · Still private

LOX (lysyl oxidase) inhibitors for treating myeloproliferative disorder-induced bone marrow fibrosis

Claim this profile

Follows are private to you and power your alerts

Updated

Sector
Biotech
Total capital
$198K
Federal grants
$198K
1 award · 2020
Rank in peer group#365 of 392
Private capital raised
None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts
None on recordNo federal contract awards found.
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

2020FEDERAL ↑EQUITY ↓Cumulative $198K$198K
2020FEDERAL ↑EQUITY ↓Cumulative $198K$198K

Latest events

  • Federal grantHealth and Human S · Phase I · Development of lysyl oxidase inhibitors for the treatment of fibrosis$198K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 392 peers

Line = median

Biotech · Molecule

  • Federal grantsBelow median

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

  • EXESALIBERO, INC.Similar federal contract value in Biotech · null in contracts
  • SpliceBioSimilar federal contract value in Biotech · null in contracts
  • SOUTHEASTERN BIOCHEMICALS, INC.Similar federal contract value in Biotech · null in contracts
  • QUELLTX INCSimilar federal contract value in Biotech · null in contracts
  • Sidewinder TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • BIOPROVAR CORPORATIONSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .